MX2014001626A - Preservacion asistida con vacio de productos biologicos, en particular de vacunas. - Google Patents

Preservacion asistida con vacio de productos biologicos, en particular de vacunas.

Info

Publication number
MX2014001626A
MX2014001626A MX2014001626A MX2014001626A MX2014001626A MX 2014001626 A MX2014001626 A MX 2014001626A MX 2014001626 A MX2014001626 A MX 2014001626A MX 2014001626 A MX2014001626 A MX 2014001626A MX 2014001626 A MX2014001626 A MX 2014001626A
Authority
MX
Mexico
Prior art keywords
vaccines
assisted
preservation
vacuum
biological products
Prior art date
Application number
MX2014001626A
Other languages
English (en)
Other versions
MX350096B (es
Inventor
Noel Yves Henri Jean Genin
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of MX2014001626A publication Critical patent/MX2014001626A/es
Publication of MX350096B publication Critical patent/MX350096B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mechanical Engineering (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona generalmente a los campos de inmunología y tecnología de vacunas. Más específicamente, la presente invención se relaciona a métodos para vitrificar preparaciones biológicas, inclusive péptidos, antígenos, anticuerpos, células y los similares.
MX2014001626A 2011-08-12 2012-05-31 Preservación asistida con vacío de productos biológicos, en particular de vacunas. MX350096B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490987P 2011-08-12 2011-08-12
PCT/US2012/040230 WO2013025274A1 (en) 2011-08-12 2012-05-31 Vacuum -assisted preservation of biological products, in particular of vaccines

Publications (2)

Publication Number Publication Date
MX2014001626A true MX2014001626A (es) 2015-03-09
MX350096B MX350096B (es) 2017-08-25

Family

ID=46246235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001626A MX350096B (es) 2011-08-12 2012-05-31 Preservación asistida con vacío de productos biológicos, en particular de vacunas.

Country Status (13)

Country Link
US (2) US10166188B2 (es)
EP (1) EP2741740B1 (es)
JP (1) JP6041361B2 (es)
CN (1) CN103841963B (es)
CA (1) CA2844927C (es)
DK (1) DK2741740T3 (es)
EA (1) EA031229B1 (es)
ES (1) ES2626297T3 (es)
HU (1) HUE035774T2 (es)
LT (1) LT2741740T (es)
MX (1) MX350096B (es)
SI (1) SI2741740T1 (es)
WO (1) WO2013025274A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110734844B (zh) 2014-06-09 2023-05-30 索姆尼尔环球控股有限公司 毛细管辅助玻璃化方法和装置
EP3548078A1 (en) 2016-11-30 2019-10-09 Boehringer Ingelheim Animal Health USA Inc. Attenuated swine influenza vaccines and methods of making and use thereof
CN107043740A (zh) * 2017-05-10 2017-08-15 浙江美保龙生物技术有限公司 一种mdbk细胞培养液及其制备方法、使用方法
CN107217029A (zh) * 2017-06-08 2017-09-29 浙江美保龙生物技术有限公司 一种pk‑15细胞培养液及其制备方法、使用方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US11287185B1 (en) 2020-09-09 2022-03-29 Stay Fresh Technology, LLC Freeze drying with constant-pressure and constant-temperature phases
CN113046412B (zh) * 2021-03-29 2021-12-14 深圳市麦瑞科林科技有限公司 一种高安全性的非灭活型病毒保存液及制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3783098A (en) 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
US3915794A (en) 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
US4000256A (en) 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5178862A (en) 1989-12-01 1993-01-12 Parhelion Corporation Canine distemper virus vaccine and method of preparation
AT395893B (de) 1990-01-10 1993-03-25 Mayreder Kraus & Co Ing Befestigungsvorrichtung zum verbinden von bauteilen
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
ES2152304T3 (es) 1993-02-08 2001-02-01 Bayer Ag Procedimiento para el crecimiento del virus del sindrome reproductivo y respiratorio porcino y su uso en vacunas.
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US6485729B1 (en) 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
AU4954496A (en) 1995-03-17 1996-10-08 Hisamitsu Pharmaceutical Co., Inc. Gene transfer preparation
CA2214029A1 (en) 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
JPH08333277A (ja) 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
FR2741806B1 (fr) 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
CA2256333A1 (en) * 1996-05-29 1997-12-04 Victor Bronshtein Long-term shelf preservation by vitrification
US6509146B1 (en) * 1996-05-29 2003-01-21 Universal Preservation Technologies, Inc. Scalable long-term shelf preservation of sensitive biological solutions and suspensions
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751223B1 (fr) 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6051238A (en) 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
FR2758986B1 (fr) 1997-01-31 1999-04-30 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
WO1999008713A1 (en) 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination by topical application of genetic vectors
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
IL139637A0 (en) 1998-05-15 2002-02-10 Quark Biotech Inc Mechanical stress induced genes, expression products therefrom, and uses thereof
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
BRPI0014142B8 (pt) * 1999-08-24 2021-05-25 Abic Biological Laboratories Ltd composição de vacina comprimida estável, e, pacote para vacinação
US6872357B1 (en) * 2000-11-22 2005-03-29 Quadrant Drug Delivery Limited Formulation of preservation mixtures containing sensitive biologicals to be stabilized for ambient temperature storage by drying
US20030064000A1 (en) * 2001-09-24 2003-04-03 Wilson Burgess Methods of sterilizing biological mixtures using stabilizer mixtures
WO2003092377A1 (en) * 2002-05-01 2003-11-13 Cryoglass Llc Cryopreservation system for liquid substances
AU2004299057B2 (en) 2003-12-17 2010-06-24 Wyeth Llc Methods for porducing storage stable viruses and immunogenic compositions thereof
US20060141483A1 (en) 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
WO2007035455A2 (en) 2005-09-16 2007-03-29 Merial Limited Stabilizers for freeze-dried vaccines
JP2009510136A (ja) 2005-10-04 2009-03-12 アルク−アベッロ エイ／エス 固体ワクチン製剤
RU2541784C2 (ru) * 2006-11-07 2015-02-20 Санофи Пастер Байолоджикс Ко. Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
JP2013515754A (ja) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規な抗体製剤
US20120222979A1 (en) * 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
WO2020053940A1 (ja) 2018-09-10 2020-03-19 株式会社Ｎｔｔドコモ ユーザ端末

Also Published As

Publication number Publication date
MX350096B (es) 2017-08-25
US10653627B2 (en) 2020-05-19
EP2741740B1 (en) 2017-05-03
HUE035774T2 (en) 2018-05-28
WO2013025274A1 (en) 2013-02-21
CA2844927C (en) 2017-10-31
CN103841963B (zh) 2018-04-24
LT2741740T (lt) 2017-08-10
JP2014521742A (ja) 2014-08-28
US20130040370A1 (en) 2013-02-14
EA201400216A1 (ru) 2014-06-30
US10166188B2 (en) 2019-01-01
SI2741740T1 (sl) 2017-08-31
DK2741740T3 (en) 2017-06-06
EP2741740A1 (en) 2014-06-18
ES2626297T3 (es) 2017-07-24
EA031229B1 (ru) 2018-12-28
US20190070117A1 (en) 2019-03-07
CA2844927A1 (en) 2013-02-21
CN103841963A (zh) 2014-06-04
JP6041361B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
MX350096B (es) Preservación asistida con vacío de productos biológicos, en particular de vacunas.
MX363307B (es) Plataformas para suministro de antigenos.
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
MY187874A (en) Antibody formulations
SG195306A1 (en) Purification of biological products by constrained cohydration chromatography
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
IN2014CN03892A (es)
MX337397B (es) Vacunas anti-virales dirigidas a celulas que presentan antigeno.
WO2010104749A8 (en) Antigen presenting cell targeted cancer vaccines
MX2011009438A (es) Anticuerpos anti-cd40 y usos de los mismos.
MY170720A (en) Antibody formulations
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MX2014005372A (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
WO2012145238A3 (en) Methods for reducing an adverse immune response to a foreign antigen in human using cd4-binding molecules
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
WO2014004385A3 (en) Anti-cancer vaccines
UA112747C2 (uk) Лікарський засіб і спосіб профілактики інфікування віл, профілактики і лікування захворювань, що викликаються віл або асоційовані з віл, у тому числі сніду
NZ725212A (en) Group a streptococcus vaccine
PL2575872T3 (pl) Zatężanie antygenów szczepionkowych grypy bez liofilizacji
WO2012173819A3 (en) Anti-cd3 therapies
MX368484B (es) Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
IN2014MN01381A (es)
WO2012149525A3 (en) Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: MERIAL, INC.

FG Grant or registration